Human Genome Epidemiology Literature Finder
Records 1 - 10 (of 10 Records) |
Query Trace: Thrombosis and CYP3A5[original query] |
---|
Perioperative genomic profiles using structure-specific oligonucleotide probes. Clinical medicine & research 2009 Sep 7 (3): 69-84. Hogan Kirk J, Burmester James K, Caldwell Michael D, Hogan Quinn H, Coursin Douglas B, Green Dawn N, Selzer Rebecca M R, Broderick Thomas P, Rusy Deborah A, Poroli Mark, Lutz Anna L, Sanders Allison M, Oldenburg Mary C, Koelbl James A, de Arruda-Indig Monika, Halsey Jennifer L, Day Stephen P, Domanico Michael |
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European heart journal 2010 Dec 31 (24): 3046-53. Harmsze Ankie M, van Werkum Jochem W, Ten Berg Jurriën M, Zwart Bastiaan, Bouman Heleen J, Breet Nicoline J, van 't Hof Arnoud W J, Ruven Hendrik J T, Hackeng Christian M, Klungel Olaf H, de Boer Anthonius, Deneer Vera H |
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart (British Cardiac Society) 2012 Sep 98 (18): 1366-72. Park Kyung Woo, Kang Jeehoon, Park Jin Joo, Yang Han-Mo, Lee Hae-Young, Kang Hyun-Jae, Koo Bon-Kwon, Oh Byung-Hee, Park Young-Bae, Kim Hyo-S |
The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Biochemical pharmacology 2012 Apr 83 (7): 903-8. Namazi Soha, Kojuri Javad, Khalili Andia, Azarpira Neg |
Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy. Journal of thrombosis and haemostasis : JTH 2013 Aug 11 (8): 1617-9. Blondon M, Wiggins K L, Harrington L B, Psaty B M, Smith N |
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC. Cardiovascular interventions 2013 Nov 6 (11): 11. Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G |
Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study. Genetic testing and molecular biomarkers 2017 Sep . Ju Shang, Gao Yu, Cao Xin, Zhang Xiao-Fu, Yan Cheng-Cheng, Liu Feng-To |
Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention. Cardiovascular toxicology 2018 May . Mahdieh Nejat, Rabbani Ahmad, Firouzi Ata, Zahedmehr Ali, Hoseinimoghaddam Maryam, Saedi Sedigheh, Sanati Hamidreza, Basiri Hosseinali, Noohi Feridoun, Rabbani Bahareh, Maleki Maj |
Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm. Journal of thrombosis and haemostasis : JTH 2021 Aug . Ndadza Arinao, Muyambo Sarudzai, Mntla Pindile, Wonkam Ambroise, Chimusa Emile, Kengne Andre P, Ntsekhe Mpiko, Dandara Coll |
Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study. Frontiers in pharmacology 2022 12 13 1032995. Azzahhafi Jaouad, Bergmeijer Thomas O, van den Broek Wout W A, Chan Pin Yin Dean R P P, Rayhi Senna, Peper Joyce, Bor Willem L, Claassens Daniel M F, van Schaik Ron H N, Ten Berg Jurriën |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: